In the examined mouse models, lung tumors recruited immune system brake cells to their edges. A team from Columbia University identified the responsible cell group and blocked the signaling pathway in mice. Afterward, cancer-fighting immune cells became more active and tumor burden declined. The researchers found similar cell patterns in human data and tissue samples. However, the intervention was tested only in mice. This represents a concrete new target and not yet a drug or proof of effect in patients.
The tumor builds itself a protective ring
The newly described cells belong to cancer-associated fibroblasts. These are connective tissue cells in the environment around a tumor. In the study published on August 11 in Nature Immunology, the new subgroup carries the name imCAF. Its distinctive feature is the protein CHL1.
These cells accumulate at the edge of lung tumors and produce the signaling molecule CXCL9. It attracts regulatory T cells bearing the receptor CXCR3. Such T cells normally prevent excessive immune reactions. In the tumor, however, they dampen precisely those CD8 T cells that could attack cancer cells. The classification by Lung Cancer Europe summarizes the mechanism as an axis connecting imCAF, CXCL9, and CXCR3-bearing regulatory T cells.
The team genetically disabled either the receptor CXCR3 in regulatory T cells or the signaling molecule CXCL9 in surrounding connective tissue cells in mice. In both variants, fewer brake T cells accumulated at the tumor. The CD8 T cells became more active and tumor burden decreased. A statement from Columbia University describes the result as a possible approach to making existing immunotherapies more effective.
The human evidence remains limited
The researchers found a similar gene pattern in a single-cell atlas containing 4,869 human lung fibroblasts from 43 people across six studies. In a separate analysis of tumor data from the TCGA-LUAD database, higher CHL1 values correlated with lower activity of cancer-fighting cells and shorter progression-free survival. This is a correlation. It does not prove that CHL1 causes the worse prognosis.
The limitation becomes even clearer in tissue imaging. The team examined samples from six people with lung adenocarcinoma carrying a specific KRAS mutation. One sample was uninterpretable due to its high mucin content. In the remaining five, CHL1-positive cells and regulatory T cells lay close together. Five interpretable tumors provide a biological clue, not a basis for clinical decision-making.
Caution is particularly important with lung cancer. According to the latest report from Germany's public health authority, approximately 58,300 people developed it in 2023. The relative five-year survival rate was 25 percent for women and 19 percent for men. An early laboratory finding must not be marketed as a cure promise given these numbers.
In comparison: Two targets that became therapies
That a molecular mechanism can later prove therapeutically relevant is shown by two earlier pathways. The first led to pembrolizumab. The antibody releases an immune brake via PD-1. The U.S. National Cancer Institute reports a median overall survival of 30 months with pembrolizumab in a study of 305 previously untreated people with high PD-L1 expression, compared to 14.2 months with chemotherapy. The five-year assessment of the KEYNOTE-024 trial showed an overall survival after five years of 31.9 percent with pembrolizumab versus 16.3 percent with chemotherapy. This was a randomized phase three trial in humans and thus a substantially higher level of evidence than the new imCAF work.
The second pathway targeted the KRAS G12C mutation, long considered difficult to attack. The FDA granted sotorasib accelerated approval on May 28, 2021, for previously treated people with KRAS-mutated non-small cell lung cancer. In the trial published in the New England Journal of Medicine, 126 people received treatment. 37 percent responded to the therapy. The median duration of response was eleven months. According to the U.S. National Cancer Institute, accelerated approval applies specifically to this mutation and prior systemic therapy.
Both comparisons also illustrate the distance to the new discovery. Pembrolizumab and sotorasib were tested in clinical trials for dosing and side effects, and validated in clearly defined patient groups. The new work names neither an approved inhibitor nor a human trial for the imCAF axis.
Why this new target still matters
The advance consists of three parts. First, the cell group possesses CHL1 as a marker identifying it in tumor tissue. Second, CXCL9 describes a concrete signaling molecule and CXCR3 the matching receptor. Third, disabling both sides in the mouse model pointed in the same direction. This makes the finding more verifiable than a mere statistical correlation.
Any therapy would need to be highly selective. CXCR3-bearing regulatory T cells also protect healthy tissue from misdirected immune attacks. If disabled throughout the body, inflammation or autoimmune reactions could emerge. The study itself therefore names selective disruption of the particularly suppressive cells within the tumor as a conceivable approach.
Three hurdles until human testing
Before a clinical trial, three things are needed. First, a drug that sufficiently and selectively blocks the imCAF axis. Second, confirmation of the mechanism in larger and more diverse human tumor groups. Third, animal studies must clarify whether the enhanced immune activity remains manageable. Only then can researchers test whether the approach alone or combined with existing immunotherapies helps people live longer without disease progression. The good news is therefore precise: A previously invisible part of the protective barrier now has a name, a signaling pathway, and several measurable attack points.